Consistent with these findings, co-treatment with MI and CBP/p300 (GNE-049 and GNE-781) or MOZ (WM1119) inhibitor synergistically induced loss of viability in AML cells with MLL1-r or mtNPM1. This evidence concerns the gene KMT2A and acute myeloid leukemia.